Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M121,752Revenue $M38,760Net Margin (%)12.9Z-Score0
Enterprise Value $M121,752EPS $1.9Operating Margin %18.0F-Score0
P/E(ttm))28.2Cash Flow Per Share $0Pre-tax Margin (%)16.8Higher ROA y-yN
Price/Book2.110-y EBITDA Growth Rate %0Quick Ratio0Cash flow > EarningsN
Price/Sales3.55-y EBITDA Growth Rate %0Current Ratio0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %17.6ROA % (ttm)7.7Higher Current Ratio y-yN
Dividend Yield %3.9Insider Buy (3m)0ROE % (ttm)13.3Less Shares Outstanding y-yN
Payout Ratio %90.0Shares Outstanding M2,642ROI % (ttm)4.2Gross Margin Increase y-yN

Gurus Latest Trades with SNY

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYNWQ Managers 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 48.861%Add 22.12%2,941,923
SNYHOTCHKIS & WILEY 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 48.861%Add 18.16%11,692,693
SNYNWQ Managers 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 48.861%Add 22.12%2,941,923
SNYCharles Brandes 2014-12-31 Add0.21%$44.4 - $55
($48.49)
$ 48.861%Add 14.36%2,571,795
SNYJames Barrow 2014-12-31 Add0.15%$44.4 - $55
($48.49)
$ 48.861%Add 8.87%30,804,459
SNYDavid Dreman 2014-12-31 Buy $44.4 - $55
($48.41)
$ 48.861%New holding, 1102 sh.1,102
SNYBill Nygren 2014-09-30 Add0.27%$50.89 - $57.29
($53.73)
$ 48.86-9%Add 14.55%5,670,000
SNYPRIMECAP Management 2014-09-30 Add0.05%$50.89 - $57.29
($53.73)
$ 48.86-9%Add 29.21%3,891,356
SNYJean-Marie Eveillard 2014-09-30 Reduce-0.07%$50.89 - $57.29
($53.73)
$ 48.86-9%Reduce -94.39%34,157
SNYBill Nygren 2014-06-30 Add0.9%$51.23 - $54.54
($53.08)
$ 48.86-8%Add 90.38%4,950,000
SNYPRIMECAP Management 2014-06-30 Add0.03%$51.23 - $54.54
($53.08)
$ 48.86-8%Add 21.59%3,011,646
SNYNWQ Managers 2014-06-30 Reduce-1.31%$51.23 - $54.54
($53.08)
$ 48.86-8%Reduce -52.34%2,602,503
SNYScott Black 2014-06-30 Reduce-0.39%$51.23 - $54.54
($53.08)
$ 48.86-8%Reduce -27.57%178,985
SNYJohn Hussman 2014-06-30 Sold Out -0.09%$51.23 - $54.54
($53.08)
$ 48.86-8%Sold Out0
SNYScott Black 2014-03-31 Buy 1.4%$47.77 - $53.63
($50.64)
$ 48.86-4%New holding, 247100 sh.247,100
SNYBill Nygren 2014-03-31 Buy 1.1%$47.77 - $53.63
($50.68)
$ 48.86-4%New holding, 2600000 sh.2,600,000
SNYHOTCHKIS & WILEY 2014-03-31 Add0.75%$47.77 - $53.63
($50.68)
$ 48.86-4%Add 65.83%9,804,594
SNYJames Barrow 2014-03-31 Add0.39%$47.77 - $53.63
($50.68)
$ 48.86-4%Add 22.72%27,790,116
SNYNWQ Managers 2014-03-31 Reduce-0.17%$47.77 - $53.63
($50.68)
$ 48.86-4%Reduce -6.39%5,460,055
SNYHOTCHKIS & WILEY 2013-12-31 Add0.27%$48.75 - $54
($51.57)
$ 48.86-5%Add 23.53%5,912,375
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SNY David Dreman 2014-12-311,10200New Buy
SNY NWQ Managers 2014-12-312,941,9230.111.6+22.12%
SNY HOTCHKIS & WILEY 2014-12-3111,692,6930.441.9+18.16%
SNY Charles Brandes 2014-12-312,571,7950.11.7+14.36%
SNY Mario Gabelli 2014-12-315,19500+13.43%
SNY PRIMECAP Management 2014-12-314,287,2070.160.2+10.17%
SNY James Barrow 2014-12-3130,804,4591.171.9+8.87%
SNY Dodge & Cox 2014-12-3143,272,8001.641.8+0.01%
SNY Bill Nygren 2014-12-315,670,0000.211.5
SNY Jean-Marie Eveillard 2014-12-3134,15700
SNY Warren Buffett 2014-12-313,905,8750.150.16
SNY Ken Fisher 2014-12-3113,085,0330.51.2-0.46%
SNY Scott Black 2014-12-31176,4600.011.1-1.09%
SNY Third Avenue Management 2014-12-3110,70400.01-13.02%
SNY Bill Nygren 2014-09-305,670,0000.212.1+14.55%
Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2015-01-29Buy97,118$95-48.57view
Sanofi10% Owner 2015-01-26Buy843,699$2240.11-97.82view
Sanofi10% Owner 2015-01-22Buy196,251$93.17-47.56view
Sanofi10% Owner 2014-03-25Buy344,448$66.88-26.94view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67537.03view

Press Releases about SNY :

    Quarterly/Annual Reports about SNY:

      News about SNY:

      Articles On GuruFocus.com
      Oh là là! Looking for Dividend Yield? Explore France Feb 27 2015 
      FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 
      Dodge & Cox 2014 Equity Year in Review Feb 19 2015 
      The Reasons That Make Pfizer A Worthy Hold. Feb 05 2015 
      Causeway Capital Global Value Equity Q4 2014 Commentary Feb 04 2015 
      Causeway International Value Fund Q4 2014 Commentary Jan 20 2015 
      Dodge & Cox's Stock Fund Q4 2014 Commentary Jan 20 2015 
      Guru Stocks at 52-Week Lows: GOOG, VZ, HSBC, SNY, TOT Jan 12 2015 
      SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sanofi SA and It Jan 02 2015 
      Guru Stocks at 52-Week Lows: HSBC, SNY, WBK, DCM, BBVA Dec 23 2014 


      More From Other Websites
      What structural reforms are required by different countries? Feb 27 2015
      Merrimack Pharmaceuticals Q4 Loss Narrower Than Expected - Analyst Blog Feb 27 2015
      Who Might Buy Puma Biotechnology? Feb 27 2015
      Oculus Innovative Sciences No One Trick Pony With Launch of New Animal Healthcare Division Feb 27 2015
      Afrezza's Initial Sales Create Buying Opportunity Feb 27 2015
      7:17 am Sanofi-Aventis announces Toujeo receives positive opinion from the European Regulatory... Feb 27 2015
      What You Should Know Before Watching Vice's Special About Curing Cancer Feb 26 2015
      MannKind: 'Encouraged By Early Feedback' on Afrezza Launch Feb 26 2015
      BioMarin's Q4 Loss Narrower than Expected, Gives 2015 View - Analyst Blog Feb 26 2015
      MannKind: Nothing to See Here Feb 25 2015
      MannKind Reports Narrower Y/Y Loss in Q4, Afrezza in Focus - Analyst Blog Feb 25 2015
      VIVUS Q4 Loss Wider than Expected, Qsymia Disappoints - Analyst Blog Feb 25 2015
      Big pharma invests big money in research and development Feb 23 2015
      Lysosomal Therapeutics to use $20M to develop, test Parkinson's drug Feb 20 2015
      Afrezza Will Succeed But Initial Sales Likely To Disappoint Feb 20 2015
      FDA Fast-Track Should Accrete Significant Value to This Overlooked Biotech Feb 20 2015
      Sales have been slower than expected. It takes time to educate the physician. Feb 20 2015
      5 Tasks for Sanofi's New CEO Feb 20 2015
      Genzyme's parent company names Bayer exec as its new CEO Feb 20 2015
      Sanofi's new CEO Feb 19 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK